1-[(2E)-2-丁烯-1-基]-1H-咪唑 | 31410-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-[(2E)-2-丁烯-1-基]-1H-咪唑
• 英文名称: 1-(2-butenyl)imidazole
• 英文别名: 1-crotylimidazole；1-but-2-enyl-1H-imidazole；N-Crotyl-imidazol；1-[(E)-but-2-enyl]imidazole
• CAS: 31410-00-1
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: AKBNVSZFPAJJDT-NSCUHMNNSA-N

物化性质

• 沸点：
  240.5±19.0 °C(Predicted)
• 密度：
  0.93±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  三环(7.4.0.0.2,8)-1(12),9,11-三烯-8-醇 、 1-[(2E)-2-丁烯-1-基]-1H-咪唑 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以126 mg的产率得到
  参考文献：
  名称：

  Tandem Decarboxylative Allylation and Fragmentation of Allyl Benzocyclobutenyl Carbonates: Access to ortho-Functionalized Aryls from Aryl Bromides

  摘要：

  Allyl benzocyclobutyl carbonates yield ortho-allyl alpha-aryl ketones through a palladium-catalyzed decarboxylative allylation, fragmentation, and cross-coupling process.

  DOI：

  10.1055/s-0031-1290943
• 作为产物：
  描述：

  咪唑 、 N-<(E)-2-butenyloxycarbonyl>imidazole 以 氘代乙腈 为溶剂， 反应 16.0h， 生成 1-[(2E)-2-丁烯-1-基]-1H-咪唑
  参考文献：
  名称：

  On the reactivity of imidazole carbamates and ureas and their use as esterification and amidation reagents

  摘要：

  The optimization, substrate scope, and mechanism of esterification and amidation of carboxylic acids mediated by imidazole-based reagents are discussed. The innate reactivity of carbonylimidazole reagents with a range of nucleophiles is also explored. New reagents developed for the synthesis of alpha,beta-unsaturated esters are described, as are reagents for the preparation of tertiary amides directly from carboxylic acids. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.09.057

文献信息

• Palladium-Catalyzed Dehydrative Cross-Coupling of Allylic Alcohols and <i>N</i>-Heterocycles Promoted by a Bicyclic Bridgehead Phosphoramidite Ligand and an Acid Additive
  作者：Kyungjun Kang、Jaewook Kim、Ansoo Lee、Woo Youn Kim、Hyunwoo Kim

  DOI：10.1021/acs.orglett.6b00001

  日期：2016.2.5

  A mild and efficient dehydrative cross-coupling reaction between allylic alcohols and N-heterocycles using palladium catalysis is reported. A bicyclic bridgehead phosphoramidite (briphos) ligand together with Pd(dba)2 is a highly efficient catalyst, and an acid additive involved in the rate-determining step promotes the catalytic cycle. The coupling reaction of allylic alcohols with N-heterocycles

  报道了使用钯催化的在烯丙基醇和N-杂环之间的温和且有效的脱水交叉偶联反应。双环桥头亚磷酰胺（briphos）配体与Pd（dba）2一起是高效催化剂，速率确定步骤中涉及的酸添加剂促进了催化循环。烯丙基醇与包括咪唑，苯并咪唑和三唑的N-杂环的偶合反应在温和的反应条件下进行，使用钯/硫磷和五氟苯酚的收率很高。
• IMIDAZO PYRIDINE DERIVATIVES
  申请人：Taracido Ivan Cornella

  公开号：US20090291942A1

  公开（公告）日：2009-11-26

  The invention relates to novel imidazopyridine derivatives and to their use in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases.

  这项发明涉及新型咪唑吡啶衍生物及其在治疗可能涉及血管生成和/或疼痛的疾病和紊乱中的应用，包括自身免疫和炎症性疾病。
• Pharmaceutically active imidazole derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04284641A1

  公开（公告）日：1981-08-18

  The invention relates to a class of imidazoles substituted by cycloalkyl or cycloalkenyl which have pharmacological properties making them useful in medicine, in particular in the prophylaxis and treatment of thrombo-embolic disorders.

  这项发明涉及一类由环烷基或环烯基取代的咪唑类化合物，具有药理特性，使它们在医学上特别在预防和治疗血栓栓塞性疾病方面有用。
• Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0000951A1

  公开（公告）日：1979-03-07

  The invention relates to the use in medicine of 1-alkylimidazoles of formula in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms; n is 0 or 1; and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof. The 1-alkylimidazoles in which n is 0 and R ist cycloalkyl or cycloalkenyl are novel, as are those when A and R together form an alkenyl radical. Methods of preparing the 1-alkylimidazoles are disclosed. The 1-alkylimidazoles have pharmacological properties of use in medicine, in particular for the treatment or prophylaxis of thrombo-embolic disorders.

  本发明涉及式 1-烷基咪唑的医药用途。 其中 A 是 1 至 3 个碳原子的直链或支链、饱和或不饱和的无环烃基；n 是 0 或 1；和 R 是 4 至 9 个碳原子的环烷基或环烯烃基，并可选择被一个、两个、三个或多个烷基取代，每个烷基含有 1 至 4 个碳原子，或者，当 n 为 1 时，A 和 R 共同形成 4 至 7 个碳原子的烷基或 4 至 9 个碳原子的烯基或炔基，咪唑为游离基或其药学上可接受的盐。 n为0、R为环烷基或环烷烯基时的1-烷基咪唑是新颖的，A和R共同形成烯基时的1-烷基咪唑也是新颖的。 本发明公开了制备 1-烷基咪唑的方法。 1-烷基咪唑具有药理特性，可用于医药，特别是用于治疗或预防血栓栓塞性疾病。
• Cephalosporin derivatives
  申请人：Otsuka Kagaku Kabushiki Kaisha

  公开号：EP0214600A2

  公开（公告）日：1987-03-18

  A cephalosporin compound substituted by imidazolium ring in 3-position of cephem having the following formula (I), and pharmaceutically acceptable salt thereof, wherein R1 is an organic residue known in β-lactam antibiotics, R2 is hydrogen atom or methoxy, n is 0 or 1, A is a nitrogen-containing group constituting imidazolium ring, is useful as an agent for preventing and treating bacterial infections.

  一种在头孢菌素的 3 位被咪唑环取代的头孢菌素化合物，具有下式(I)及其药学上可接受的盐、 其中 R1 是β-内酰胺类抗生素中已知的有机残基，R2 是氢原子或甲氧基，n 是 0 或 1，A 是构成咪唑环的含氮基团，可作为预防和治疗细菌感染的药物。